# tables/efficacy/ttet01.qmd result_v1 development

    Code
      print(data_snap[[i]])
    Output
                                           A: Drug X        B: Placebo      C: Combination 
                                            (N=134)           (N=134)           (N=132)    
      —————————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)             58 (43.3%)        58 (43.3%)        69 (52.3%)   
        Earliest contributing event                                                        
          Death                               58                58                69       
      Patients without event (%)          76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                               
        Median                                NA                NA                9.4      
          95% CI                           (9.3, NA)         (9.4, NA)         (7.6, NA)   
        25% and 75%-ile                     5.6, NA           5.6, NA           5.0, NA    
        Range                           0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                                
        p-value (log-rank)                                    0.9998            0.1541     
        Hazard Ratio                                           1.00              1.29      
        95% CI                                             (0.69, 1.44)      (0.91, 1.83)  
      6 Months                                                                             
        Patients remaining at risk            97                97                90       
        Event Free Rate (%)                  72.39             72.39             68.18     
        95% CI                          (64.82, 79.96)    (64.82, 79.96)    (60.24, 76.13) 
        Difference in Event Free Rate                          0.00              -4.21     
          95% CI                                          (-10.71, 10.71)   (-15.18, 6.77) 
          p-value (Z-test)                                    1.0000            0.4525     
      12 Months                                                                            
        Patients remaining at risk            49                48                37       
        Event Free Rate (%)                  56.72             56.72             47.73     
        95% CI                          (48.33, 65.11)    (48.33, 65.11)    (39.21, 56.25) 
        Difference in Event Free Rate                          0.00              -8.99     
          95% CI                                          (-11.86, 11.86)   (-20.95, 2.97) 
          p-value (Z-test)                                    1.0000            0.1406     
      —————————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      —————————————————————————————————————————————————————————————————————————————————————
      

# tables/efficacy/ttet01.qmd result_v2 development

    Code
      print(data_snap[[i]])
    Output
                                        A: Drug X        B: Placebo      C: Combination 
                                         (N=134)           (N=134)           (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)          58 (43.3%)        58 (43.3%)        69 (52.3%)   
      Patients without event (%)       76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                            
        Median                             NA                NA                9.4      
          95% CI                        (9.3, NA)         (9.4, NA)         (7.6, NA)   
        25% and 75%-ile                  5.6, NA           5.6, NA           5.0, NA    
        Range                        0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                             
        p-value (log-rank)                                 0.9998            0.1541     
        Hazard Ratio                                        1.00              1.29      
        95% CI                                          (0.69, 1.44)      (0.91, 1.83)  
      6 Months                                                                          
        Patients remaining at risk         97                97                90       
        Event Free Rate (%)               72.39             72.39             68.18     
        95% CI                       (64.82, 79.96)    (64.82, 79.96)    (60.24, 76.13) 
      12 Months                                                                         
        Patients remaining at risk         49                48                37       
        Event Free Rate (%)               56.72             56.72             47.73     
        95% CI                       (48.33, 65.11)    (48.33, 65.11)    (39.21, 56.25) 
      ——————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      ——————————————————————————————————————————————————————————————————————————————————
      

# tables/efficacy/ttet01.qmd result_v3 development

    Code
      print(data_snap[[i]])
    Output
                                         A: Drug X        B: Placebo      C: Combination 
                                          (N=134)           (N=134)           (N=132)    
      ———————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)           58 (43.3%)        58 (43.3%)        69 (52.3%)   
        Earliest contributing event                                                      
          Death                             58                58                69       
      Patients without event (%)        76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                             
        Median                              NA                NA                9.4      
          90% CI                         (9.6, NA)         (9.6, NA)         (7.7, NA)   
        25% and 75%-ile                   5.6, NA           5.6, NA           5.0, NA    
        Range                         0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                              
        p-value (log-rank)                                  0.9998            0.1541     
        Hazard Ratio                                         1.00              1.29      
        95% CI                                           (0.69, 1.44)      (0.91, 1.83)  
      12 Months                                                                          
        Patients remaining at risk          49                48                37       
        Event Free Rate (%)                56.72             56.72             47.73     
        90% CI                        (49.37, 63.41)    (49.37, 63.41)    (40.42, 54.66) 
      Difference in Event Free Rate                          0.00              -8.99     
        97.5% CI                                        (-13.57, 13.57)   (-22.66, 4.69) 
        p-value (Z-test)                                    1.0000            0.1406     
      ———————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      ———————————————————————————————————————————————————————————————————————————————————
      

# tables/efficacy/ttet01.qmd result_v4 development

    Code
      print(data_snap[[i]])
    Output
                                           A: Drug X        B: Placebo      C: Combination 
                                            (N=134)           (N=134)           (N=132)    
      —————————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)             58 (43.3%)        58 (43.3%)        69 (52.3%)   
        Earliest contributing event                                                        
          Death                               58                58                69       
      Patients without event (%)          76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                               
        Median                                NA                NA                9.4      
          95% CI                           (9.3, NA)         (9.4, NA)         (7.6, NA)   
        25% and 75%-ile                     5.6, NA           5.6, NA           5.0, NA    
        Range                           0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                                
        p-value (log-rank)                                    0.9998            0.1541     
        Hazard Ratio                                           1.00              1.29      
        95% CI                                             (0.69, 1.44)      (0.91, 1.83)  
      Stratified Analysis                                                                  
        p-value (log-rank)                                    0.9978            0.1733     
        Hazard Ratio                                           1.00              1.27      
        95% CI                                             (0.69, 1.44)      (0.90, 1.81)  
      12 Months                                                                            
        Patients remaining at risk            49                48                37       
        Event Free Rate (%)                  56.72             56.72             47.73     
        95% CI                          (48.33, 65.11)    (48.33, 65.11)    (39.21, 56.25) 
        Difference in Event Free Rate                          0.00              -8.99     
          95% CI                                          (-11.86, 11.86)   (-20.95, 2.97) 
          p-value (Z-test)                                    1.0000            0.1406     
      —————————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      —————————————————————————————————————————————————————————————————————————————————————
      

# tables/efficacy/ttet01.qmd result_v5 development

    Code
      print(data_snap[[i]])
    Output
                                           A: Drug X        B: Placebo      C: Combination 
                                            (N=134)           (N=134)           (N=132)    
      —————————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)             58 (43.3%)        58 (43.3%)        69 (52.3%)   
        Earliest contributing event                                                        
          Death                               58                58                69       
      Patients without event (%)          76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                               
        Median                                NA                NA                9.4      
          95% CI                           (9.3, NA)         (9.4, NA)         (7.6, NA)   
        25% and 75%-ile                     5.6, NA           5.6, NA           5.0, NA    
        Range                           0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                                
        p-value (log-rank)                                    0.9998            0.1541     
        Hazard Ratio                                           1.00              1.29      
        95% CI                                             (0.69, 1.44)      (0.91, 1.83)  
      6 Months                                                                             
        Patients remaining at risk            97                97                90       
        Event Free Rate (%)                  72.39             72.39             68.18     
        95% CI                          (64.82, 79.96)    (64.82, 79.96)    (60.24, 76.13) 
        Difference in Event Free Rate                          0.00              -4.21     
          95% CI                                          (-10.71, 10.71)   (-15.18, 6.77) 
          p-value (Z-test)                                    1.0000            0.4525     
      —————————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      —————————————————————————————————————————————————————————————————————————————————————
      

# tables/efficacy/ttet01.qmd result_v6 development

    Code
      print(data_snap[[i]])
    Output
                                           A: Drug X        B: Placebo      C: Combination 
                                            (N=134)           (N=134)           (N=132)    
      —————————————————————————————————————————————————————————————————————————————————————
      Patients with event (%)             58 (43.3%)        58 (43.3%)        69 (52.3%)   
        Earliest contributing event                                                        
          Death                               58                58                69       
      Patients without event (%)          76 (56.7%)        76 (56.7%)        63 (47.7%)   
      Time to Event (Months)                                                               
        Median                                NA                NA                9.4      
          95% CI                           (9.3, NA)         (9.4, NA)         (7.6, NA)   
        25% and 75%-ile                     5.6, NA           5.6, NA           5.0, NA    
        Range                           0.5 to 16.4 {1}   0.9 to 16.3 {1}   0.5 to 16.3 {1}
      Unstratified Analysis                                                                
        p-value (log-rank)                                    0.9998            0.1541     
        p-value (wald)                                        0.9998            0.1552     
        p-value (likelihood)                                  0.9998            0.1543     
          Hazard Ratio                                         1.00              1.29      
            95% CI                                         (0.69, 1.44)      (0.91, 1.83)  
      12 Months                                                                            
        Patients remaining at risk            49                48                37       
        Event Free Rate (%)                  56.72             56.72             47.73     
        95% CI                          (48.33, 65.11)    (48.33, 65.11)    (39.21, 56.25) 
        Difference in Event Free Rate                          0.00              -8.99     
          95% CI                                          (-11.86, 11.86)   (-20.95, 2.97) 
          p-value (Z-test)                                    1.0000            0.1406     
      —————————————————————————————————————————————————————————————————————————————————————
      
      {1} - Censored observation: range maximum
      —————————————————————————————————————————————————————————————————————————————————————
      

